课题基金 / 基金详情

Immersive Team-Based Design in Undergraduate Bioengineering Education

Immersive Team-Based Design in Undergraduate Bioengineering Education
本科生物工程教育中的沉浸式团队设计
批准号:
8244404
负责人:
Amy Elizabeth Herr
金额:
$4.32万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-01 至 2016-03-31

项目摘要

项目成果

Amy Elizabeth Herr的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):加州大学伯克利分校生物工程系(BioE)已经确定了迫切的社会需求,需要在具有挑战性的医疗技术领域培养伯克利分校的下一批生物工程师。鉴于最近的课程和项目发展,对加州大学伯克利分校即将毕业的生物工程师以及更广泛的美国产生重大和可扩展的积极培训影响的时机恰到好处。我们建议加强和显著扩展现有的(新的)以项目为基础的核心课程,并让我们的毕业大四学生参加课程前的“临床沉浸”和课程后的“翻译沉浸”。拟议的教学和经验相结合的培训将全面介绍转化医学领域的创新--目的是用实际操作的临床工作补充理论知识。我们利用现有的以项目为基础的课程作为教育项目的核心,通过新提议的(A)课程前(暑期)“临床沉浸式”课程,以确定加州大学旧金山医学中心尚未满足的临床需求,(B)在与加州大学旧金山分校临床“客户”一起扩展的高级设计项目课程期间,增强团队项目机会和导师,以及(C)项目后“翻译沉浸式”学期,学生利用新获得的工程设计技能和对翻译挑战的鉴赏力,聘请一系列临床专家和行业领袖,了解工程在医学中的作用。通过R25,我们将通过三个具体目标培训本科生理解、从事和领导医疗技术创新:1)挑战我们的学生识别和定义生物医学问题,以实现有意义的生物工程解决方案;2)介绍使用开放式生物医学问题的工程设计方法,同时营造一个促进和鼓励跨学科和基于团队的创新的环境;3)提供一个受保护的培训期,在此期间我们的学生通过发明、原型制作和测试新技术、诊断和疗法来创新,这些新技术、诊断和疗法符合真正的临床需求,并与临床和商业领袖进行磋商。 公共卫生相关性:通过转化医学的教学和体验式培训增加新生物工程师的数量,将增加和改善以需求为中心的医学创新。工科学生在转化医学培训中面临挑战,即获得临床经验和指导。在加州大学伯克利分校与加州大学旧金山分校和周边医疗项目的合作下,加州大学伯克利分校提议的R25将在生物工程学士学位课程的最后一年引入一项“翻译培训”流水线计划。
英文摘要
DESCRIPTION (provided by applicant): UC Berkeley's Department of Bioengineering (BioE) has identified a compelling societal need to educate the next cadre of Berkeley's bioengineers in the challenging area of medical technology. Owing to recent course and program development, the timing is right for a substantial and scalable positive training impact on UC Berkeley's graduating bioengineers and, more broadly, the US. We propose to enhance and significantly extend an existing (new) core project-based course and engage our graduating seniors in both a pre-course 'Clinical Immersion' and post-course 'Translational Immersion' periods. The proposed combined didactic and experiential training will provide a comprehensive introduction to innovating in the arena of translational medicine -- with the aim of supplementing theoretical knowledge with hands-on clincial work. We leverage an existing project-based course as the kernel for a educational program that will expose senior bioengineering undergraduates to translational medicine through newly proposed (a) pre-course (summer) 'Clinical Immersion' periods to identify unmet clinical needs at UC San Francisco Medical Centers, (b) enhanced team-project opportunities and mentors during an expanded senior design project course with UCSF clinical 'clients', and (c) a post-project 'Translational Immersion' semester in which students use their newly acquired engineering design skills & appreciation for translational challenges to engage a spectrum of clinical experts & industry leaders to understand the role of engineering in medicine. Through the R25, we will train undergraduates to understand, engage in, and lead medical technology innovation through three Specific Aims: 1) Challenge our students to identify and define biomedical problems to achieve meaningful bioengineering solutions, 2) Introduce engineering design approaches using open-ended biomedical problems, while fostering an environment in which interdisciplinary and team-based innovation are promoted & encouraged, 3) Provide a protected training period during which our students innovate around open biomedical problems through invention, prototyping, and testing of new technologies, diagnostics, and therapies which meet a true clinical need in consultation with clinical and business leaders. PUBLIC HEALTH RELEVANCE: Increasing the number of new bioengineers with didactic & experiential training in translational medicine will increase and improve needs-centered innovation in medicine. Engineering students face challenges in translational medicine training, namely in gaining clinical experience and mentoring. In collaboration with UCSF and surrounding medical programs, UC Berkeley's proposed R25 will introduce a 'translational training' pipeline program in the culminating year of the BioE B.S. curriculum.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MULTIPLEXED ISOFORM QUANTIFICATION IN HER2-POSITIVE BREAST CANCER
  • 批准号:
    10362550
  • 项目类别:
  • 资助金额:
    $34.53万
  • 财政年份:
    2021
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
MULTIPLEXED ISOFORM QUANTIFICATION IN HER2-POSITIVE BREAST CANCER
  • 批准号:
    10583566
  • 项目类别:
  • 资助金额:
    $35.05万
  • 财政年份:
    2021
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
Advanced Cancer Classification via Single-Cell Electrophoretic Cytopathology
  • 批准号:
    9482979
  • 项目类别:
  • 资助金额:
    $145.39万
  • 财政年份:
    2017
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
Multiplexed isoform quantification in HER2-positive breast cancer
  • 批准号:
    9390766
  • 项目类别:
  • 资助金额:
    $34.78万
  • 财政年份:
    2015
  • 负责人:
    Amy Elizabeth Herr
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: